GSS 0.00% 76.0¢ genetic signatures limited

Ann: Chairman's Address to Shareholders, page-25

  1. 43 Posts.
    lightbulb Created with Sketch. 5
    COVID is the medium term benefit for this company, it gets to show case it’s technology, while others pay for it. The sales team gets out there (slower than normal) and over time will grow the customer base. It really is dependant on how the C team manage sales rollout and allocate capital. Not the short term negativity around a large part of the market at the moment.
 
watchlist Created with Sketch. Add GSS (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.